These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31818850)

  • 1. Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
    Mohammed A; Miller MS; Lubet RA; Suen CS; Sei S; Shoemaker RH; Juliana MM; Moeinpour FL; Grubbs CJ
    Cancer Prev Res (Phila); 2020 Mar; 13(3):273-282. PubMed ID: 31818850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
    Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K
    Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
    Lubet RA; Scheiman JM; Bode A; White J; Minasian L; Juliana MM; Boring DL; Steele VE; Grubbs CJ
    Cancer Prev Res (Phila); 2015 Apr; 8(4):296-302. PubMed ID: 25762530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin.
    Lubet RA; Huebner K; Fong LY; Altieri DC; Steele VE; Kopelovich L; Kavanaugh C; Juliana MM; Soong SJ; Grubbs CJ
    Carcinogenesis; 2005 Mar; 26(3):571-8. PubMed ID: 15591090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression.
    Lubet RA; Kumar A; Fox JT; You M; Mohammed A; Juliana MM; Grubbs CJ
    Bladder Cancer; 2021; 7(3):335-345. PubMed ID: 38993610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
    Steele VE; Rao CV; Zhang Y; Patlolla J; Boring D; Kopelovich L; Juliana MM; Grubbs CJ; Lubet RA
    Cancer Prev Res (Phila); 2009 Nov; 2(11):951-6. PubMed ID: 19892664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
    Nicastro HL; Grubbs CJ; Margaret Juliana M; Bode AM; Kim MS; Lu Y; You M; Milne GL; Boring D; Steele VE; Lubet RA
    Cancer Prev Res (Phila); 2014 Feb; 7(2):246-54. PubMed ID: 24346344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
    Lubet RA; Fischer SM; Steele VE; Juliana MM; Desmond R; Grubbs CJ
    Int J Cancer; 2008 Nov; 123(10):2254-9. PubMed ID: 18712722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Salim EI; Wanibuchi H; Morimura K; Kim S; Yano Y; Yamamoto S; Fukushima S
    Carcinogenesis; 2000 Feb; 21(2):195-203. PubMed ID: 10657958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment.
    Okajima E; Ozono S; Endo T; Majima T; Tsutsumi M; Fukuda T; Akai H; Denda A; Hirao Y; Okajima E; Nishino H; Nir Z; Konishi Y
    Jpn J Cancer Res; 1997 Jun; 88(6):543-52. PubMed ID: 9263531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.
    Tyagi A; Raina K; Singh RP; Gu M; Agarwal C; Harrison G; Glode LM; Agarwal R
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3248-55. PubMed ID: 18089718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
    Miyazawa K; Miyamoto S; Suzuki R; Yasui Y; Ikeda R; Kohno H; Yano M; Tanaka T; Hata K; Suzuki K
    Oncol Rep; 2007 Feb; 17(2):297-304. PubMed ID: 17203164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Okazaki K; Yamagishi M; Son HY; Imazawa T; Furukawa F; Nakamura H; Nishikawa A; Masegi T; Hirose M
    Nutr Cancer; 2002; 42(2):211-6. PubMed ID: 12416262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive effect of 1,4-phenylene diisothiocyanate on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
    Sugie S; Vinh PQ; Rahman KM; Ushida J; Kohno H; Suzuki R; Hara A; Quang le B; Tanaka T; Mori H
    Int J Cancer; 2005 Nov; 117(4):524-30. PubMed ID: 15929075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
    Vinh PQ; Sugie S; Tanaka T; Hara A; Yamada Y; Katayama M; Deguchi T; Mori H
    Jpn J Cancer Res; 2002 Jan; 93(1):42-9. PubMed ID: 11802807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor mRNA levels as a biomarker for short-term N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis bioassay.
    Wakui S; Mutou T; Takahashi H; Ikegami M; Wanibuchi H; Fukushima S
    J Appl Toxicol; 2015 Feb; 35(2):181-90. PubMed ID: 24888239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promotion by sodium L-ascorbate in rat two-stage urinary bladder carcinogenesis is dependent on the interval of administration.
    Chen TX; Wanibuchi H; Murai T; Kitano M; Yamamoto S; Fukushima S
    Jpn J Cancer Res; 1999 Jan; 90(1):16-22. PubMed ID: 10076560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of FT-207 on bladder cancer in rats induced by BBN. II: The effect of oral administration of FT-207 during oncogenesis of bladder cancer].
    Okajima E; Hiramatsu T; Kihoin K; Ijuin M; Hirao Y; Ohara S; Babaya K; Tanaka M; Maruyama Y
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):473-9. PubMed ID: 6820898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
    Lubet RA; Lu Y; Bode AM; You M; Verney ZM; Steele VE; Townsend R; Juliana MM; Grubbs CJ
    Oncol Rep; 2011 May; 25(5):1389-97. PubMed ID: 21369704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder.
    Rao KV; Detrisac CJ; Steele VE; Hawk ET; Kelloff GJ; McCormick DL
    Carcinogenesis; 1996 Jul; 17(7):1435-8. PubMed ID: 8706245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.